Çağlar Çağlayan1, Jordan S Goldstein2, Turgay Ayer1, Ashish Rai3, Christopher R Flowers2. 1. H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia. 2. Winship Cancer Institute of Emory University, Atlanta, Georgia. 3. Outcomes Research, Surveillance and Health Services Research Program, American Cancer Society Inc, Atlanta, Georgia.
Abstract
BACKGROUND: Despite effective therapies, outcomes for diffuse large B-cell lymphoma (DLCBL) remain heterogeneous in older individuals due to comorbid diseases and variations in disease biology. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, the authors conducted a multistate survival analysis of 11,780 patients with DLBCL who were aged ≥65 years at the time of diagnosis (2002-2009). Cox proportional hazards models were used to specify the impact of prognostic factors on overall survival and cause-specific deaths, and the Aalen-Johansen estimator was used to project the course of DLBCL over time with or without standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). RESULTS: Advanced age (hazard ratio [HR] for ages 71-75 years: 1.25; HR for ages 76-80 years: 1.46; HR for ages 81-85 years: 1.88; and HR for age ≥86 years: 2.26), DLBCL stage (HR for Ann Arbor stage II: 1.28; HR for stage III: 1.54; and HR for stage IV: 1.95), Charlson Comorbidity Index (CCI) ≥1 (HR for CCI of 1, 1.15; and HR for CCI >1, 1.37), and not being married (HR, 1.12) were associated with an increased risk of DLBCL-specific death. Being female (HR, 0.91) and of higher socioeconomic status (HR, 0.91) were associated with a lower risk of DLBCL-related mortality after therapy. For patients treated with R-CHOP (3610 patients), the risk of death due to DLBCL was 14.0% and 18.6%, respectively, at 2 and 5 years of treatment and plateaued afterward, confirming a 5-year "cure" point while receiving R-CHOP among older patients. CONCLUSIONS: Conducting a survival analysis over a large data set, the current study evaluated competing risks for death within a multistate modeling framework, and identified age, sex, and CCI as risk factors for DLBCL-specific and other causes of death.
BACKGROUND: Despite effective therapies, outcomes for diffuse large B-cell lymphoma (DLCBL) remain heterogeneous in older individuals due to comorbid diseases and variations in disease biology. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, the authors conducted a multistate survival analysis of 11,780 patients with DLBCL who were aged ≥65 years at the time of diagnosis (2002-2009). Cox proportional hazards models were used to specify the impact of prognostic factors on overall survival and cause-specific deaths, and the Aalen-Johansen estimator was used to project the course of DLBCL over time with or without standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). RESULTS: Advanced age (hazard ratio [HR] for ages 71-75 years: 1.25; HR for ages 76-80 years: 1.46; HR for ages 81-85 years: 1.88; and HR for age ≥86 years: 2.26), DLBCL stage (HR for Ann Arbor stage II: 1.28; HR for stage III: 1.54; and HR for stage IV: 1.95), Charlson Comorbidity Index (CCI) ≥1 (HR for CCI of 1, 1.15; and HR for CCI >1, 1.37), and not being married (HR, 1.12) were associated with an increased risk of DLBCL-specific death. Being female (HR, 0.91) and of higher socioeconomic status (HR, 0.91) were associated with a lower risk of DLBCL-related mortality after therapy. For patients treated with R-CHOP (3610 patients), the risk of death due to DLBCL was 14.0% and 18.6%, respectively, at 2 and 5 years of treatment and plateaued afterward, confirming a 5-year "cure" point while receiving R-CHOP among older patients. CONCLUSIONS: Conducting a survival analysis over a large data set, the current study evaluated competing risks for death within a multistate modeling framework, and identified age, sex, and CCI as risk factors for DLBCL-specific and other causes of death.
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Christopher R Flowers; Pareen J Shenoy; Uma Borate; Kevin Bumpers; Tanyanika Douglas-Holland; Nassoma King; Otis W Brawley; Joseph Lipscomb; Mary Jo Lechowicz; Rajni Sinha; Rajinder S Grover; Leon Bernal-Mizrachi; Jeanne Kowalski; Will Donnellan; Angelina The; Vishnu Reddy; David L Jaye; James Foran Journal: Leuk Lymphoma Date: 2013-02
Authors: Andre Wieringa; Karin Boslooper; Mels Hoogendoorn; Peter Joosten; Tim Beerden; Huib Storm; Robby E Kibbelaar; Gerrit J Veldhuis; Harmen van Kamp; Bastiaan van Rees; Hanneke C Kluin-Nelemans; Nic J G M Veeger; Eric N van Roon Journal: Br J Haematol Date: 2014-02-07 Impact factor: 6.998
Authors: Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Jean L Koff; Ashley D Staton; Jagpreet Chhatwal; Christopher R Flowers Journal: Leuk Lymphoma Date: 2015-12-15
Authors: Adrián Mosquera Orgueira; Jose Ángel Díaz Arías; Miguel Cid López; Andrés Peleteiro Raíndo; Alberto López García; Rosanna Abal García; Marta Sonia González Pérez; Beatriz Antelo Rodríguez; Carlos Aliste Santos; Manuel Mateo Pérez Encinas; Máximo Francisco Fraga Rodríguez; José Luis Bello López Journal: Hemasphere Date: 2022-03-25
Authors: Müjde Durmaz; Otto Visser; Eduardus F M Posthuma; Rolf E Brouwer; Djamila E Issa; Daphne de Jong; King H Lam; Nicole M A Blijlevens; Josée M Zijlstra; Martine E D Chamuleau; Pieternella J Lugtenburg; Marie José Kersten; Avinash G Dinmohamed Journal: Blood Cancer J Date: 2022-03-09 Impact factor: 11.037
Authors: Willem Daneels; Michael Rosskamp; Gilles Macq; Estabraq Ismael Saadoon; Anke De Geyndt; Fritz Offner; Hélène A Poirel Journal: Front Oncol Date: 2022-02-28 Impact factor: 6.244
Authors: Ewa Paszkiewicz-Kozik; Wojciech Michalski; Michał Taszner; Monika Mordak-Domagała; Joanna Romejko-Jarosińska; Wanda Knopińska-Posłuszny; Jacek Najda; Anna Borawska; Monika Chełstowska; Monika Świerkowska; Anna Dąbrowska-Iwanicka; Agata Malenda; Agnieszka Druzd-Sitek; Robert Konecki; Beata Kumiega; Michał Osowiecki; Beata Ostrowska; Tomasz Szpila; Marcin Szymański; Łukasz Targoński; Katarzyna Domańska-Czyż; Lidia Popławska; Sebastian Giebel; Andrzej Lange; Andrzej Pluta; Jan Maciej Zaucha; Grzegorz Rymkiewicz; Jan Walewski Journal: Br J Haematol Date: 2022-04-01 Impact factor: 8.615